Press Releases

FDA Grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma to Can-Fite BioPharma

Can-Fite BioPharma Ltd , a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration has granted Orphan...

ELC Group launches new software subsidiary Pharma eReport to provide complete EVMPD compliance solution

ELC Group, the pan-European pharmaceutical regulatory affairs organisation, today announces the launch of a new subsidiary, Pharma eReport – a software and services company that delivers a comprehensive EVMPD compliance solution for pharmaceutical regulatory professionals.  ...

Provepharm announces impressive trading and financial results for 2011

Provepharm, which is specialized in the development of pharmaceutical applications, announces today very healthy trading and financial results for 2011. The company broke even for the first time last year, when its revenues amounted to EUR three million. ...

DNA Electronics CEO Professor Chris Toumazou To Address Scripps “Future of Genomic Medicine” Conference

DNA Electronics Ltd. a developer of semiconductor solutions for real-time DNA and RNA detection, today announces that DNA Electronics Chairman and CEO Professor Chris Toumazou FRS will be an invited speaker at the upcoming “The Future of Genomic Medicine...

Ferrer announces best-in-class results in phase I for Lorediplon in insomnia

Ferrer, a privately-held Spanish pharmaceutical company with full vertical integration from R&D to distribution, today announces that it has completed phase I clinical trials of Lorediplon in insomnia. The trials demonstrated the orally available compound has a best-in-class...

Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK

Cambridge, UK, February 8 2012 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today formally announces that it has established its global headquarters in Cambridge, UK. The opening of the new global HQ follows a year of...

RBCC Negotiates Funding Terms With n3D

Rainbow Biosciences, the biotech division of Rainbow Coral Corp. announced today that it’s on the cusp of a major breakthrough in its business relationship with n3D Biosciences. Last week, management from RBCC and n3D convened to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read